Hepatitis C virus-related cryoglobulinemic vasculitis: Emerging trends in therapy

Arthritis and Rheumatism

Volumn 64, Issue 3, 2012, Pages 604-608

  St clair, E William ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BOCEPREVIR; CORTICOSTEROID; CRYOGLOBULIN; CYCLOPHOSPHAMIDE; PEGINTERFERON ALPHA; PREDNISONE; RIBAVIRIN; RITUXIMAB; TELAPREVIR; VIRUS RNA;

ANTIVIRAL THERAPY; CRYOGLOBULINEMIA; DRUG EFFICACY; DRUG SAFETY; GENE TRANSLOCATION; GENOTYPE; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTENTION TO TREAT ANALYSIS; LOW DRUG DOSE; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT; VASCULITIS; VIRUS LOAD;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIVIRAL AGENTS; CRYOGLOBULINEMIA; DRUG RESISTANCE, VIRAL; FEMALE; HEPATITIS C, CHRONIC; HUMANS; IMMUNOLOGIC FACTORS; MALE;

EID: 84857694125     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.34326     Document Type: Review

References (30)

1. Meltzer M, Franklin EC,. Cryoglobulinemia-a study of twenty-nine patients. I. IgG and IgM cryoglobulins and factors affecting cryoprecipitability. Am J Med 1966; 40: 828-36.
2. Brouet JC, Clauvel JP, Danon F, Klein M, Seligmann M,. Biologic and clinical significance of cryoglobulins: a report of 86 cases. Am J Med 1974; 57: 775-88.
3. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M,. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral genome. Science 1989; 244: 359-62.
4. Ferri C, Greco F, Longombardo G, Palla P, Moretti A, Marzo E, et al. Antibodies to hepatitis C virus in patients with mixed cryoglobulinemia. Arthritis Rheum 1991; 34: 1606-10.
5. Ferri C, Marzo E, Longombardo G, Lombardini F, La Civita L, Vanacore R, et al. Interferon-α in mixed cryoglobulinemic patients: a randomized, crossover, controlled trial. Blood 1993; 81: 1132-6.
6. Dammacco F, Sansonno D, Han JH, Shyamala V, Cornacchiulo V, Iacobelli AR, et al. Natural interferon-α versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study. Blood 1994; 84: 3336-43.
7. Misiani R, Bellavita P, Fenili D, Vicari O, Marchesi D, Sironi PL,. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994; 330: 751-6.
8. Cacoub P, Lidove O, Maisonobe T, Duhaut P, Thibault V, Ghillani P, et al. Interferon-α and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum 2002; 46: 3317-26.
9. Saadoun D, Resche-Rigon M, Thibault V, Piette JC, Cacoub P,. Antiviral therapy for hepatitis C virus-associated mixed cryoglobulinemic vasculitis: a long-term followup study. Arthritis Rheum 2006; 54: 3696-706.
10. Cornec D, Avouac J, Youinou P, Saraux A,. Critical analysis of rituximab-induced serological changes in connective tissue diseases. Autoimmunity Rev 2009; 8: 515-9.
11. De Vita S, Quartuccio L, Isola M, Mazzaro C, Scaini P, Lenzi M, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum 2012; 64: 847-54.
12. Sneller MC, Hu Z, Langford CA,. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum 2012; 64: 835-46.
13. Luqmani RA, Bacon PA, Moots RJ, Janssen BA, Pall A, Emery P, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. Q J Med 1994; 87: 671-8.
14. Landau DA, Saadoun D, Halfon P, Martinot-Peignoux M, Marcellin P, Fois E, et al. Relapse of hepatitis C virus-associated mixed cryoglobulinemia vasculitis in patients with sustained viral response. Arthritis Rheum 2008; 58: 604-11.
15. Dammacco F, Tucci FA, Lauletta G, Gatti P, De Re V, Conteduca V, et al. Pegylated interferon-α, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood 2010; 116: 343-53.
16. Terrier B, Saadoun D, Sene D, Sallam J, Perard L, Coppere B, et al. Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: a long-term followup study of thirty-two patients. Arthritis Rheum 2009; 60: 2531-40.
17. Petrarca A, Rigacci L, Caini P, Colagrande S, Romagnoli P, Vizutti F, et al. Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. Blood 2010; 116: 335-42.
18. Ferri C, Cacoub P, Mazzaro C, Roccatello D, Scaini P, Sebastiani M, et al. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature. Autoimmunity Rev 2011; 11: 48-55.
19. Sene D, Ghillani-Dalbin P, Amoura Z, Musset L, Cacoub P,. Rituximab may form a complex with IgMκ mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis. Arthritis Rheum 2009; 60: 3848-55.
20. Geri G, Terrier B, Semoun O, Saadoun D, Sene D, Charlotte F, et al. Surrogate markers of B cell non-Hodgkin's lymphoma in patients with hepatitis C virus-related cryoglobulinemic vasculitis. Ann Rheum Dis 2010; 69: 2177-80.
21. Hermine O, Lefrere F, Bronowicki JP, Mariette X, Jondeau K, Eclache-Saudreau V, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002; 347: 89-94.
22. Saadoun D, Suarez F, Lefrere F, Valensi F, Mariette X, Aouba A, et al. Splenic lymphoma with villous lymphocytes, associated with type II cryoglobulinemia and HCV infection: a new entity? Blood 2005; 105: 74-6.
23. Sansonno D, Lauletta G, De Re V, Tucci FA, Gatti P, Racanelli V, et al. Intrahepatic B cell clonal expansions and extrahepatic manifestations of chronic HCV infection. Eur J Immunol 2004; 34: 126-36.
24. + B cells in HCV-associated mixed cryoglobulinemia. Blood 2008; 111: 1344-56.
25. Knight GB, Gao L, Gragnani L, Elfahal MM, De Rosa FG, Gordon FD, et al. Detection of WA B cells in hepatitis C virus infection: a potential prognostic marker for cryoglobulinemic vasculitis and B cell malignancies. Arthritis Rheum 2010; 62: 2152-9.
26. Chen Z, Zhu Y, Ren Y, Tong Y, Hua X, Zhu F, et al. Hepatitis C virus protects human B lymphocytes from Fas-mediated apoptosis via E2-CD81 engagement. PLos One 2011; 6: e18933.
27. Zignego AL, Ferri C, Giannelli F, Giannini C, Caini P, Monti M, et al. Prevalence of bcl-2 rearrangement in patients with hepatitis C virus-related mixed cryoglobulinemia with or without B-cell lymphomas. Ann Intern Med 2002; 137: 571-80.
28. Strader DB, Wright T, Thomas DL, Seef LB,. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 1147-71.
29. Saadoun D, Rigon MR, Sene D, Terrier B, Karras A, Perard L, et al. Rituximab plus Peg-interferon-α/ribavirin compared with Peg-interferon-α/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood 2010; 116: 326-34.
30. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seef LB,. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-44.